Literature DB >> 30543889

Use of a water-based probiotic to treat common gut pathogens.

Cornelius C Dodoo1, Paul Stapleton1, Abdul W Basit1, Simon Gaisford2.   

Abstract

This work reports the anti-pathogenic effect of a commercially available water-based probiotic suspension, Symprove™, against three commonly encountered infectious organisms; Escherichia coli, methicillin-resistant Staphylococcus aureus (MRSA) and Shigella sonnei. An isothermal calorimetric assay was used to the monitor growth of the species individually and in binary combinations, while colony plate counting was used to enumerate viable cell numbers. It was observed that all pathogenic species were faster growing than the probiotic bacteria in Symprove™ after inoculation into growth medium yet in all instances bacterial enumeration at the end of the experiments revealed a significant reduction in the pathogen population compared with the controls. A control population between 108 and 109 CFU/ml was obtained for E. coli and S. sonnei whilst approximately 106 CFU/ml was obtained for MRSA. Upon co-incubation for 48 h, no viable counts were obtained for E. coli; a 4-log reduction was obtained for S. sonnei whilst MRSA numbers were down to less than 10 cells/ml. The results show that Symprove™ has antipathogenic activity against E. coli, S. sonnei and MRSA.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Infectious diseases; Lactobacilli; MRSA; Shigella sonnei, Escherichia coli

Mesh:

Substances:

Year:  2018        PMID: 30543889     DOI: 10.1016/j.ijpharm.2018.11.075

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  2 in total

1.  Harnessing machine learning for development of microbiome therapeutics.

Authors:  Laura E McCoubrey; Moe Elbadawi; Mine Orlu; Simon Gaisford; Abdul W Basit
Journal:  Gut Microbes       Date:  2021 Jan-Dec

2.  Influence of probiotic bacteria on gut microbiota composition and gut wall function in an in-vitro model in patients with Parkinson's disease.

Authors:  Jonas Ghyselinck; Lynn Verstrepen; Frédéric Moens; Pieter Van Den Abbeele; Arnout Bruggeman; Jawal Said; Barry Smith; Lynne Ann Barker; Caroline Jordan; Valentina Leta; K Ray Chaudhuri; Abdul W Basit; Simon Gaisford
Journal:  Int J Pharm X       Date:  2021-07-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.